SOURCE: Symbollon Pharmaceuticals, Inc.

September 18, 2008 11:38 ET

Symbollon to Exhibit at the Natural Products Expo East

FRAMINGHAM, MA--(Marketwire - September 18, 2008) - Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA) is pleased to announce that it will be exhibiting at the Natural Products Expo East 2008 being held October 16th through 18th at the Boston Convention & Exhibition Center in Boston. Symbollon will be launching its dietary supplement, IoGen™ at Expo East. IoGen is formulated to promote breast health for women. Over 40% of the nation's $51.4 billion natural products sales are generated on the eastern seaboard. Expo East is expecting over 20,000 attendees comprised of retailer buyers, distributors, brokers, manufacturers, suppliers, press and industry members.

"The timing of Expo East meshes nicely with the planned launch of IoGen," stated Paul C. Desjourdy, President and Chief Executive Officer of Symbollon. "In addition to online retail sales, we plan to explore additional distribution channels for IoGen. We believe that Expo East will provide us with significant access to additional retail and wholesale distribution channels for the product."

About Symbollon Pharmaceuticals, Inc. (OTCBB: SYMBA)

Symbollon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products based on its molecular iodine technology for women's healthcare and antimicrobials uses. For more information about Symbollon, please visit the company's website at http://www.symbollon.com.

Forward-Looking Statement

This news release contains statements by the Company that involve risks and uncertainties and may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including, but not limited to, the risks and uncertainties associated with whether (i) we will be able to proceed with the commercialization of IoGen, (ii) Symbollon will be able to obtain the resources necessary to continue operations as a going concern, (iii) the Company will be able to enter into new arrangements with corporate partners, (iv) management and the Board of Directors will be able to maximize shareholder value by leveraging the Company's proprietary technology, and (v) such other factors as may be disclosed from time-to-time in the Company's reports as filed with the Securities and Exchange Commission.

Contact Information

  • CONTACT:
    Paul C. Desjourdy
    President and CEO
    Symbollon Pharmaceuticals, Inc.
    (508) 620-7676, x202
    www.symbollon.com